Servier Signs Agreements with Hybrigenics and Cortex

Servier, the largest French privately-owned pharmaceutical company, has linked up with fellow French firm Hybrigenics to discover first-in-class drugs for a selection of diseases, notably cancer. The companies have signed a licence and research collaboration agreement in the field of deubiquitinating enzymes (DUBs) to be applied to oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular

Continue Reading